This is an open-label single center trial to study improvements in symptom bother and quality
of life in overactive bladder patients self titrating solifenacin 5mg and 10 mg. The study is
designed to reflect real world conditions in typical male and female OAB patients presenting
for treatment.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health